MicroRNA-124 rs531564 Polymorphism and Cancer Risk: A Meta-analysis |
Li, Wen-Jing
(Medical Research Center, the Affiliated Hospital of Nanjing Medical University, Changzhou No.2 People's Hospital)
Wang, Yong (Medical Research Center, the Affiliated Hospital of Nanjing Medical University, Changzhou No.2 People's Hospital) Gong, Yu (Medical Research Center, the Affiliated Hospital of Nanjing Medical University, Changzhou No.2 People's Hospital) Tu, Chao (Medical Research Center, the Affiliated Hospital of Nanjing Medical University, Changzhou No.2 People's Hospital) Feng, Tong-Bao (Medical Research Center, the Affiliated Hospital of Nanjing Medical University, Changzhou No.2 People's Hospital) Qi, Chun-Jian (Medical Research Center, the Affiliated Hospital of Nanjing Medical University, Changzhou No.2 People's Hospital) |
1 | Ahn DH, Rah H, Choi YK, et al (2013). Association of the miR- 146aC>G, miR-149T>C, miR-196a2T>C, and miR-499A>G polymorphisms with gastric cancer risk and survival in the Korean population. Mol Carcinog, 52, 39-51. |
2 | Ambros V (2004). The functions of animal microRNAs. Nature, 431, 350-5. DOI |
3 | Bartel DP (2009). MicroRNAs: target recognition and regulatory functions. Cell, 136, 215-33. DOI |
4 | Calin GA, Croce CM (2006). MicroRNA signatures in human cancers. Nat Rev Cancer, 6, 857-66. DOI |
5 | DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. DOI |
6 | Dikeakos P, Theodoropoulos G, Rizos S, et al (2014). Association of the miR-146aC>G, miR-149T>C, and miR- 196a2T>C polymorphisms with gastric cancer risk and survival in the Greek population. Mol Biol Rep, 41, 1075-80. DOI |
7 | Ebert MS, Sharp PA (2012). Roles for microRNAs in conferring robustness to biological processes. Cell, 149, 515-24. DOI |
8 | Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. DOI |
9 | Esquela-Kerscher A, Slack FJ (2006). Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer, 6, 259-69. DOI |
10 | Fabian MR, Sonenberg N (2012). The mechanics of miRNAmediated gene silencing: a look under the hood of miRISC. Nat Struct Mol Biol, 19, 586-93. DOI |
11 | Furuta M, Kozaki KI, Tanaka S, et al (2010). miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis, 31, 766-76. DOI |
12 | Gao LB, Bai P, Pan XM, et al (2011). The association between two polymorphisms in pre-miRNAs and breast cancer risk: a meta-analysis. Breast Cancer Res Treat, 125, 571-4. DOI |
13 | Hatley ME, Patrick DM, Garcia MR, et al (2010). Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell, 18, 282-93. DOI |
14 | He L, Hannon GJ (2004). MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet, 5, 522-31. DOI |
15 | Hu CB, Li QL, Hu JF, et al (2014). miR-124 inhibits growth and invasion of gastric cancer by targeting ROCK1. Asian Pac J Cancer Prev, 15, 6543-6. DOI |
16 | Jansson MD, Lund AH (2012). MicroRNA and cancer. Mol Oncol, 6, 590-610. DOI |
17 | Ji T, Zheng ZG, Wang FM, et al (2014). Differential microRNA expression by Solexa sequencing in the sera of ovarian cancer patients. Asian Pac J Cancer Prev, 15, 1739-43. DOI |
18 | Jinushi T, Shibayama Y, Kinoshita I, et al (2014). Low expression levels of microRNA-124-5p correlated with poor prognosis in colorectal cancer via targeting of SMC4. Cancer Med, 3, 1544-52. DOI |
19 | Kong YW, Ferland-McCollough D, Jackson TJ, et al (2012). microRNAs in cancer management. Lancet Oncol, 13, 249-58. DOI |
20 | Krol J, Loedige I, Filipowicz W (2010). The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet, 11, 597-610. DOI |
21 | Kutanzi KR, Yurchenko OV, Beland FA, et al (2011). MicroRNA-mediated drug resistance in breast cancer. Clin Epigenetics, 2, 171-85. DOI |
22 | Li L, Luo J, Wang B, et al (2013). Microrna-124 targets flotillin-1 to regulate proliferation and migration in breast cancer. Mol Cancer, 12, 163. DOI |
23 | Li W, Zang W, Liu P, et al (2014). MicroRNA-124 inhibits cellular proliferation and invasion by targeting Ets-1 in breast cancer. Tumour Biol, 35, 10897-904. DOI |
24 | Lian H, Wang L, Zhang J (2012). Increased risk of breast cancer associated with CC genotype of Has-miR-146a Rs2910164 polymorphism in Europeans. PLoS ONE, 7, 31615. DOI |
25 | Link A, Kupcinskas J, Wex T, et al (2012). Macro-role of microRNA in gastric cancer. Dig Dis, 30, 255-67. DOI |
26 | Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48. |
27 | Pasquinelli AE (2012). MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet, 13, 271-82. DOI |
28 | Peng XH, Huang HR, Lu J, et al (2014). MiR-124 suppresses tumor growth and metastasis by targeting Foxq1 in nasopharyngeal carcinoma. Mol Cancer, 13, 186. DOI |
29 | Pritchard CC, Cheng HH, Tewari M (2012). MicroRNA profiling: approaches and considerations. Nat Rev Genet, 13, 358-69. |
30 | Ruan K, Fang X, Ouyang G (2009). MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett, 285, 116-26. DOI |
31 | Suarez Y, Sessa WC (2009). MicroRNAs as novel regulators of angiogenesis. Circ Res, 104, 442-54. DOI |
32 | Tong N, Xu B, Shi D, et al (2014). Hsa-miR-196a2 polymorphism increases the risk of acute lymphoblastic leukemia in Chinese children. Mutat Res Fundam Mol Mech Mutagen, 759, 16-21. DOI |
33 | Wan HY, Li QQ, Zhang Y, et al (2014). MiR-124 represses vasculogenic mimicry and cell motility by targeting amotL1 in cervical cancer cells. Cancer Lett, 355, 148-58. DOI |
34 | Wang J, Bi J, Liu X, et al (2012). Has-miR-146a polymorphism (rs2910164) and cancer risk: a meta-analysis of 19 casecontrol studies. Mol Biol Rep, 39, 4571-9. DOI |
35 | Woolf B (1955). On estimating the relation between blood group and disease. Ann Hum Genet, 19, 251-3. DOI |
36 | Wu H, Zhang J (2014). miR-124 rs531564 polymorphism influences genetic susceptibility to cervical cancer. Int J Clin Exp Med, 7, 5847-51. |
37 | Xiong X, Cheng J, Liu X, et al (2014). [Correlation analysis between miR-124 rs531564 polymorphisms and susceptibility to cervical cancer]. Nan Fang Yi Ke Da Xue Xue Bao, 34, 210-3. |
38 | Yin J, Wang X, Zheng L, et al (2013). Hsa-miR-34b/c rs4938723 T>C and hsa-miR-423 rs6505162 C>A polymorphisms are associated with the risk of esophageal cancer in a Chinese population. PLoS ONE, 8, 80570. DOI |
39 | Zhang J, Huang X, Xiao J, et al (2014a). Pri-miR-124 rs531564 and pri-miR-34b/c rs4938723 polymorphisms are associated with decreased risk of esophageal squamous cell carcinoma in Chinese populations. PLoS ONE, 9, 100055. DOI |
40 | Zhang T, Wang J, Zhai X, et al (2014b). MiR-124 retards bladder cancer growth by directly targeting CDK4. Acta Biochim Biophys Sin (Shanghai), 46, 1072-9. DOI |
![]() |